Open Access
Subscription Access
On Shapes of ADR Report Accumulation Data for Banned Drugs
Adverse drug reactions (ADRs) are a matter of great concern in drug research. This study focuses on drugs which have been banned or withdrawn, due to serious problem of adverse reactions. Our attempt is to develop insights through plotting of data on cumulative counts of ADR reports. These data have been sourced from www.vigiaccess.org. Our expectation is that once a drug is banned/withdrawn, its count of ADR reports should fall precipitously and remain there. Instead a variety of shapes is encountered. These include linear, exponential and sigmoidal. We suggest that these curves can be useful in comparing safety of drugs.
Keywords
Adverse Drug Reactions, Curve Fitting, Side Effects, Withdrawn Drugs.
User
Font Size
Information
- Fikadu, B. D. et al., Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase. Trop. Med. Int. Health, 2015, 20, 797–806.
- Ampadu, H. H. et al., Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase. Drug Safety, 2016, 39, 335–345.
- Kalaiselvan, V., Thota Prasad, Bisht, A., Singh, S. and Singh, G. N., Adverse drug reactions reporting culture in pharmacovigilance programme of India. Indian J. Med. Res., 2014, 140(4), 563–564.
- Hoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P. and Overstreet, B. M., The Weber effect and the United States food and drug administration’s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Safety, 2014, 37, 283–294; doi:10.1007/s40264-014-0150-2.
- van Puijenbroek, E. P., Diemont, W. L. and van Gischolar_mainheest, K., Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Safety, 2003, 26, 293–230.
- Michel, C. et al., Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin. Drug Invest., 2017, 1–8; doi:10.1007/s40261-017-0503-6.
- Delgado-Herrera, L., Ostroff, R. D. and Rogers, S. A., Sevoflurane: approaching the ideal inhalational anesthetic a pharmacologic, pharmacoeconomic and clinical review. CNS Drug Rev., 2001, 7, 48–120; doi:10.1111/j.1527-3458.2001.tb00190.x.
- De Hert, S. and Moerman, A., Sevoflurane. F1000Research. 4(F1000 Faculty Rev):626l, 2015; doi:10.12688/f1000research.6288.1.
Abstract Views: 317
PDF Views: 87